论文部分内容阅读
目的测定乳腺癌患者手术前血清中中期因子(MK)的含量,并讨论MK与乳腺癌的诊断和癌细胞转移之间的关系。方法以160例乳腺检查者为研究对象,采用酶联免疫检测法(ELISA)检测所有入组人员血清中MK水平,并对实验进行分析比较。结果乳腺癌组中血清MK水平明显高于良性对照组与正常对照组;淋巴结转移组的血清MK水平明显高于无转移组。结论乳腺癌患者血清MK的定量检测,有助于乳腺癌的诊断及预后诊断。因此,可以作为新的肿瘤标志物在临床推广。
Objective To determine the serum levels of midkine (MK) in patients with breast cancer and to discuss the relationship between MK and the diagnosis of breast cancer and the metastasis of cancer cells. Methods Totally 160 breast examiners were used as the research objects. The serum MK levels of all the enrolled patients were detected by enzyme - linked immunosorbent assay (ELISA), and the experiments were analyzed and compared. Results The level of serum MK in breast cancer group was significantly higher than that in benign control group and normal control group. The serum MK level in lymph node metastasis group was significantly higher than that in non-metastasis group. Conclusion The quantitative detection of serum MK in breast cancer patients is helpful for the diagnosis and prognosis diagnosis of breast cancer. Therefore, it can be used as a new tumor marker in the clinical promotion.